scholarly journals Primary Carcinoma of the Fallopian Tube: A Review of a Single Institution Experience of 8 Cases

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Shakuntala P. Nanaiah ◽  
Praveen S. Rathod ◽  
Namrata N. Rajkumar ◽  
Rajshekar Kundargi ◽  
Anbukkani Subbian ◽  
...  
Keyword(s):  
Fallopian Tube ◽  
Cytoreductive Surgery ◽  
Early Stage ◽  
Frozen Section ◽  
Single Agent ◽  
Progression Free Survival ◽  
Fallopian Tube Carcinoma ◽  
Staging Laparotomy ◽  
Primary Fallopian Tube Carcinoma ◽  
Platinum Based Chemotherapy

Aims and Objectives. To evaluate the clinicopathologic features, response to cytoreductive surgery and adjuvant platinum-based chemotherapy with or without paclitaxel.Materials and Methods. A retrospective observational study of 8 women with a histopathologic diagnosis of primary fallopian tube carcinoma (PFTC) from January 2000 to February 2013.Results. 4/8 (50%) of the women were in the early stage and an intraoperative frozen section was 100% effective in identifying fallopian tube carcinoma and then a staging laparotomy was performed. All 4/8 cases in the early stage had received and responded to single agent carboplatin and all are alive without clinical, radiological, or biochemical evidence of recurrence at the end of 2 years and the longest survivor has completed 13 years. Primary optimal cytoreductive surgery was achievable in 3/4 (75%) in advanced disease. All showed response to adjuvant paclitaxel and carboplatin (T+C), but all had succumbed to the disease following recurrence with mean progression-free survival of 19 months (range 15–21 months) and mean overall survival of 27 months (range 22–36 months).Conclusion. The pivotal role played by a frozen section in diagnosing PFTC which is rare needs to be reemphasized, therefore justifying a primary staging laparotomy in an early stage. Prolonged survival observed in this group following an optimum tailored adjuvant single agent carboplatin is worth noting.

scholarly journals Fallopian Tube Carcinoma

2019 ◽  
Vol 15 (7) ◽  
pp. 375-382 ◽  
Author(s):  
Marina Stasenko ◽  
Olga Fillipova ◽  
William P. Tew
Keyword(s):  
Fallopian Tube ◽  
Patient Survival ◽  
Gene Mutations ◽  
Adenosine Diphosphate ◽  
Parp Inhibitors ◽  
Fallopian Tube Carcinoma ◽  
Ovarian Cancers ◽  
Primary Fallopian Tube Carcinoma ◽  
Platinum Based Chemotherapy ◽  
Dose Dense

Primary fallopian tube carcinoma is a rare and difficult to cure disease. It is often grouped under the epithelial ovarian cancer umbrella, together with primary ovarian and peritoneal carcinomas. More recent evidence has suggested that epithelial ovarian cancers originate from a fallopian tube precursor. The mainstay of treatment is surgical cytoreduction and platinum-based chemotherapy. There is much debate over the best timing for surgery and the best approach to delivering the chemotherapy: traditional intravenous once every 3 weeks regimen, versus intraperitoneal, versus dose-dense intravenous regimens. Although these debates continue, novel targeted therapies, including bevacizumab and poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors, have emerged. PARP inhibitors are particularly efficacious in patients with BRCA1/2 gene mutations, and their use has been shown to prolong patient survival. This article reviews the pathologic etiology; describes the heredity, treatment challenges, and controversies; and summarizes novel therapies in primary fallopian tube carcinoma.

scholarly journals LAPAROSCOPIC MANAGEMENT OF EARLY STAGE PRIMARY FALLOPIAN TUBE CARCINOMA

2019 ◽  
Vol 5 (2) ◽  
pp. 149-151
Author(s):  
Kavitha Yogini Duraisamy ◽  
Devi Balasubramaniam ◽  
Karthikha Ravi ◽  
Aravinth Balasubramanium
Keyword(s):  
Fallopian Tube ◽  
Early Stage ◽  
Fallopian Tube Carcinoma ◽  
Laparoscopic Management ◽  
Primary Fallopian Tube Carcinoma

scholarly journals Primary Fallopian Tube Carcinoma (PFTC), A Rare Malignancy of Female Genital Tract

2019 ◽  
Vol 38 (1) ◽  
pp. 49-52
Author(s):  
Farhana Binte Rashid ◽  
Mohammad Abul Kalam Azad
Keyword(s):  
Fallopian Tube ◽  
Genital Tract ◽  
Frozen Section ◽  
Correct Diagnosis ◽  
Female Genital Tract ◽  
Total Abdominal Hysterectomy ◽  
Ultrasound Finding ◽  
Fallopian Tube Carcinoma ◽  
Primary Fallopian Tube Carcinoma ◽  
Female Genital

Background: Primary fallopian tube carcinoma (PFTC) is one of the rarest malignancies of female genital tract. It represents <1% of all gynecologic malignancies. Preoperative diagnosis is uncommon due to its rarity and non-specific symptoms. In most cases diagnosis is made during surgery or histological examination. Rarity of this type of carcinoma prompted us to report it as individual case. Case: A 40-yearold parous women presented with bilateral PFTC. The patient gave a history of lower abdominal and pelvic pain for 2 years on several occasions. An abdominal ultrasound finding showed an adnexal mass and her CA125 level was 30IU/ml (normal- <35IU/ml). Clinically she was suspected as a case of pelvic inflammatory disease (PID). She underwent Total Abdominal Hysterectomy with bilateral salpingoophorectomy. Intraoperative findings were consistent with PID. Final pathologic analysis showed bilateral primary fallopian tube carcinoma —well differentiated serous adenocarcinoma. Post operatively she was referred for oncological management. Conclusion: Malignancy should be considered in the differential diagnosis of PID especially in premenopausal age and intraoperative frozen section biopsy is crucial to make correct diagnosis and to allow appropriate surgical staging. J Bangladesh Coll Phys Surg 2020; 38(1): 49-52

Preoperative Sonographic Diagnosis of Primary Fallopian Tube Carcinoma

2002 ◽  
Vol 21 (10) ◽  
pp. 1171-1173 ◽  
Author(s):  
Jimmy H. F. Yuen ◽  
Grace C. Y. Wong ◽  
Christina H. L. Lam
Keyword(s):  
Fallopian Tube ◽  
Fallopian Tube Carcinoma ◽  
Sonographic Diagnosis ◽  
Primary Fallopian Tube Carcinoma

scholarly journals Primary Fallopian Tube Carcinoma Arising in the Setting of Chronic Pelvic Inflammatory Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Ibrahim M. Zardawi
Keyword(s):  
Ovarian Cancer ◽  
Pelvic Inflammatory Disease ◽  
Chronic Inflammation ◽  
Fallopian Tube ◽  
Inflammatory Disease ◽  
Fallopian Tube Carcinoma ◽  
Fallopian Tube Cancer ◽  
Primary Fallopian Tube Carcinoma ◽  
Gynaecological Malignancy

Primary fallopian tube cancer (PFTC) is a rare gynaecological malignancy, clinically often mistaken for pelvic inflammatory disease or ovarian cancer. Three primary fallopian tube carcinomas, arising in a background of chronic pelvic inflammatory disease (PID), are presented. The possible association between chronic PID and PFTC is discussed and a hypothesies linking these cancers with chronic inflammation is proposed.

scholarly journals The role of cytology in preoperative assessment od primary fallopian tube carcinoma: case report

2016 ◽  
Vol 52 (3) ◽  
pp. 415-420
Author(s):  
Roberta Rubeša-Mihaljević ◽  
Damjana Verša Ostojić ◽  
Morana D inter ◽  
Snježana Štemberger-Papić ◽  
Senija Eminović ◽  
...  
Keyword(s):  
Case Report ◽  
Fallopian Tube ◽  
Preoperative Assessment ◽  
Fallopian Tube Carcinoma ◽  
Primary Fallopian Tube Carcinoma

Response to selpercatinib versus prior systemic therapy in patients (pts) with RET fusion+ non-small-cell lung cancer (NSCLC).

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 9032-9032
Author(s):  
Alexander E. Drilon ◽  
Oliver Gautschi ◽  
Benjamin Besse ◽  
Vivek Subbiah ◽  
Daniel Shao-Weng Tan ◽  
...  
Keyword(s):  
Systemic Therapy ◽  
Kinase Inhibitor ◽  
Phase 1 ◽  
Single Agent ◽  
Objective Response ◽  
Progression Free Survival ◽  
Survival Duration ◽  
Prior Therapy ◽  
Platinum Based Chemotherapy ◽  
Systemic Therapies

9032 Background: Selpercatinib, a first-in-class highly selective, potent, CNS-active RET kinase inhibitor, is approved in multiple countries for treatment of RET fusion+ lung or thyroid cancers. Selpercatinib demonstrated durable antitumor activity in previously treated pts with RET fusion+ NSCLC in an ongoing Phase 1/2 trial, LIBRETTO-001 (Besse et al., ASCO 2021). Methods: Pts with RET fusion+ NSCLC enrolled in the global, multicenter, LIBRETTO-001 trial (NCT03157128; 16 countries, 89 sites). Primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival, duration of response, and safety. This post-hoc intrapatient analysis was based on a 30 March 2020 data cutoff date. Historical physician-reported best overall response (BOR) from last systemic therapy received prior to enrollment was compared with selpercatinib BOR by independent review committee per RECIST v1.1, with each patient serving as his/her own control. Results: In efficacy-evaluable pts (N = 218) who previously received platinum-based chemotherapy (chemo), median pt age was 61 years, the majority with ECOG of 0/1 (37%/61%), with a median of 2 (range: 1-15) prior systemic therapies. Overall, 57% of patients responded to selpercatinib while 16% responded to the immediate prior therapy. ORR improvements with selpercatinib were observed regardless of prior therapy: chemotherapy + immune checkpoint inhibitor (ICI) (57% vs 14%), single-agent ICI (48% vs 3%), or chemotherapy (58% vs 15%). A total of 108 patients (49%) did not respond to immediate prior therapy but responded to selpercatinib. Fewer patients had progressive disease as their BOR with selpercatinib (2%) compared to the immediate prior therapy (28%). The median duration of therapy for selpercatinib was notably extended compared with that of the immediate prior therapy (11.8 vs. 3.4 months, respectively). Conclusions: In pts with RET fusion+ NSCLC treated on LIBRETTO-001, systemic therapies administered prior to enrollment achieved less meaningful clinical benefit than selpercatinib. Selpercatinib demonstrated consistent efficacy regardless of the type of prior therapy. Clinical trial information: NCT03157128.

Sign in / Sign up

Export Citation Format

Share Document